Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 70Thoracic 4Genitourinary 4Head & Neck 3CNS 3Sarcoma 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 3Skin Neoplasms 2Thyroid Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Basal Cell 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 16Cyclophosphamide 8Nivolumab 7Gemcitabine 6Paclitaxel 5Drug Therapy 5Docetaxel 5fludarabine 4aldesleukin 4Oxaliplatin 4Fluorouracil 4Carboplatin 4ulixertinib 3spartalizumab 3Trastuzumab 3Radiotherapy 3Leucovorin 3Capecitabine 3trametinib 2tovorafenib 2pertuzumab 2pegilodecakin 2pazopanib 2palbociclib 2osimertinib 2enzalutamide 2cemiplimab 2atezolizumab 2Taxes 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Erlotinib Hydrochloride × Dermatologic × Clear all
NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡